Binding of interferon γ by glycosaminoglycans: A strategy for localization and/or inhibition of its activity

Cytokine

Volumn 11, Issue 5, 1999, Pages 313-325

  Fernandez Botran, Rafael ^a   Yan, Jun ^a   Justus, David E ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Glycosaminoglycans; Immunoregulation; Interferon ; Proteoglycans

Indexed keywords

CHONDROITIN SULFATE; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HYALURONIC ACID; IODINE 125; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; POLYLYSINE; SYNTHETIC PEPTIDE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; RADIOASSAY;

EID: 0032928765     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1998.0438     Document Type: Article

References (46)

1. Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: molecular properties, protein interactions and role in physiological processes. Physiol Rev. 71:1991;481-539.
2. Kjellen L, Lindahl A. Proteoglycans-structures and interactions. Ann Rev Biochem. 60:1991;443-475.
3. Gallagher JT, Walker A. Molecular distinctions between heparan sulphate and heparin. Biochem J. 230:1985;665-674.
4. Gallagher JT, Lyond M, Steward WP. Structure and function of heparan sulfate proteoglycans. Biochem J. 236:1986;313-325.
5. Cockwell P, Adams DH, Savage COS. Glycosaminoglycans contribute to multiple functions of vascular endothelial cells. Clin Exp Immunol. 104:1996;1-3.
6. Tanaka Y, Adams DH, Shaw S. Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes. Immunol Today. 14:1993;111-115.
7. Spillman D, Lindahl U. Glycosaminoglycan-protein interactions: a question of specificity. Curr Opin Struct Biol. 4:1994;677-682.
8. Roberts R, Gallagher J, Spooncer E, Allen TD, Bloomfield F, Dexter TM. Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature. 332:1988;376-378.
9. Lortat-Jacob H, Grimaud JA. Interferon-γC-terminal function: new working hypothesis. Heparan sulfate and heparin, new targets for IFN-γ protect, relax the cytokine and regulate its activity. Cell Mol Biol. 37:1991;253-260.
10. Lantz M, Thysell H, Nilsson E, Olson I. On the binding of tumour necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest. 88:1991;2026-2031.
11. Ramsden L, Rider CC. Selective and differential binding of interleukin (IL)-α, IL-1β, IL-2 and Il-6 to glycosaminoglycans. Eur J Immunol. 22:1992;3027-3031.
12. Tanaka Y, Adams DH, Hubscher S, Hirano H, Siebenlist U, Shaw S. T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-1β Nature. 361:1993;79-82.
13. Däubener W, Nockemann M, Gutsche M, Hadding U. Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-γ Eur. J. Immunol. 25:1995;688-692.
14. Rix DA, Douglass MS, Talbot D, Dark JH, Kirby JA. Role of glycosaminoglycans (GAGs) in regulation of the immunogenicity of human vascular endothelial cells. Clin Exp Immunol. 104:1996;60-65.
15. Sakai A, Ebina T, Ishida N. Inhibition of murine L cell interferon action by heparin. Arch Virology. 90:1986;73-85.
16. Lian RH, Kotwall GJ, Wellhausen SR, Hunt LA, Justus DE. IFN-γ-induced MHC class II gene expression is suppressed in endothelial cells by dextran sulfate. J Immunol. 157:1996;864-873.
17. Farrar MA, Schrieber RD. The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol. 11:1993;571-611.
18. Wong GHW, Clark-Lewis JL, McKimm-Breschkin JL, Harris AW, Schrader JW. Interferon-γ induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines. J Immunol. 131:1983;788-793.
19. Skoskiewicz MJ, Colvin EE, Schneeberger EE, Russell PS. Widespread and selective induction of major histocompatibility complex-determined antigens in vivo by γ interferon. J Exp Med. 162:1985;1645-1664.
20. Giacomini P, Gambari A, Sacchi PB, Fisher PB, Natali PG. Recombinant human IFN-γ, but not IFN-αor IFN-β, enhances MHC- and non-MHC-encoded glycoproteins by a protein synthesis-dependent mechanism. J Immunol. 140:1988;3073-3078.
21. Gerrard TL, Dyer DR, Zoon KC, Nedden DZ, Siegel JP. Modulation of class I and class II histocompatibility antigens on human T cell lines by IFN-γ J Immunol. 149:1988;3450-3455.
22. Bancroft GJ, Schreiber RD, Bosma GC, Bosma MJ, Unanue ER. A T cell-independent mechanism of macrophage activation by interferon γ J Immunol. 139:1987;1104-1107.
23. Ding AH, Nathan CF, Stuehr DJ. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J Immunol. 141:1988;2407-2412.
24. Taylor MW, Feng G. Relationship between interferon-γ, indoleamine 2, 3-dioxygenase, and tryptophan catabolism. FASEB J. 5:1991;2516-2522.
25. Gray PW, Goeddel DV. Cloning and expression of murine immune interferon cDNA. Proc Natl Acad Sci USA. 80:1983;5842-5846.
26. Gray PW, Leung DW, Pennica D, Yelverton E, Najarian R, Simonsen CD, Derynck R, Sherwood PJ, Wallace DM, Berger SL, Levinson AD, Goeddel DV. Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 295:1982;503-508.
27. Johnson HM, Langford MP, Lakhchaura B, Chan TS, Stanton GJ. Neutralization of native human gamma interferon (HuIFNγ) by antibodies to a synthetic peptide encoded by the 5′ end of HuIFNγ cDNA. J Immunol. 129:1982;2357-2359.
28. Magazine HI, Carter JM, Russell JK, Torres BA, Dunn BM, Johnson HM. Use of synthetic peptides to identify an N-terminal epitope on mouseγ interferon that may be involved in function. Proc Natl Acad Sci USA. 85:1988;1237-1241.
29. Jarpe MA, Johnson HM. Topology of receptor binding domains of mouse IFN-γ J Immunol. 145:1990;3304-3309.
30. Jarpe MA, Johnson HM. Structure of an epitope in an immuno-dominant region of the interferon-γ molecule that is involved in receptor interaction. J Interferon Res. 10:1990;243-252.
31. Leinikki PO, Calderon J, Luquette MH, Schreiber RD. Reduced receptor binding by a human interferon-γ fragment lacking 11 carboxyl-terminal amino acids. J Immunol. 139:1987;3360-3366.
32. Seelig G F, Widjenes J, Nagabhushan TL, Trotta PP. Evidence for a polypeptide segment at the carboxyl terminus of recombinant human γ interferon involved in expression of biologic activity. Biochemistry. 27:1988;1981-1987.
33. Sadir R, Forest E, Lortat-Jacob H. The heparan sulfate binding sequence of interferon-γincreased the on rate of the interferon-γ-interferon-γ receptor complex formation. J Biol Chem. 273:1998;10919-10925.
34. Fernandez-Botran R, Vitetta ES. A soluble, high-affinity interleukin-4-binding protein is present in the biological fluids of mice. Proc Natl Acad Sci USA. 87:1990;4202-4206.
35. Schreiber RD. Measurement of mouse and human IFNγ Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. 1991;6.8.1-6.8.8 Wiley Interscience, New York.
36. Lortat-Jacob H, Grimaud JA. Interferon-γ binds to heparan sulfate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett. 280:1991;152-154.
37. Douglas MS, Rix DA, Larnkjaer A, Dark JH, Talbot D, Kirby JA. Blockade of the interaction between interferon-γ and endothelial glycosaminoglycans: a novel strategy for immunosuppression. Transplantation Proc. 29:1997;1086-1088.
38. Ishihara M, Shaklee PN, Yang Z, Liang W, Wei Z, Stack RJ, Holme K. Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiology. 4:1994;451-458.
39. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Nature. 271:1996;1116-1120.
40. Reynolds DS, Boom WH, Abbas AK. Inhibition of B lymphocyte activation by interferon-γ J Immunol. 139:1987;767-773.
41. Lortat-Jacob H, Baltzer F, Grimaud JA. Heparin decreases the blood clearance of interferon-γ and increases its activity by limiting the processing of its carboxyl-terminal sequence. J Biol Chem. 271:1996;16139-16143.
42. Semple TU, Quinn LA, Woods LK, Moore GE. Tumor and lymphoid cell lines from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res. 38:1978;1345-1355.
43. Hoshi H, McKeehan WL. Brain- and liver cell-derived factors are required for growth of human endothelial cells in serum-free culture. Proc Natl Acad Sci USA. 81:1984;6413-6417.
44. Lowenthal JW, Castle BE, Christiansen J, Schreurs J, Rennick D, Arai N, Hoy P, Takebe T, Howard M. Expression of high-affinity receptors for murine interleukin-4 (BSF-1) on hemopoietic and nonhemopoietic cells. J Immunol. 140:1988;456-464.
45. 1). J Exp Med. 169:1989;379-391.
46. Ma Y, Hurst E, Fernandez-Botran R. Soluble cytokine receptors as carrier proteins: effects of soluble interleukin-4 receptors on the pharmacokinetics of murine interleukin-4. J Pharmacol Exp Ther. 279:1996;340-350.